Cargando…
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)
BACKGROUND: In the era of targeted therapy, whether patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are exempted from anthracycline usage in the neoadjuvant setting is controversial. OBJECTIVES: Our objective was to retrospectively analyze the differences in path...
Autores principales: | Chen, Heyan, Maimaitiaili, Amina, Liu, Zhenzhen, Ling, Rui, Zhao, Yi, Yang, Hongjian, Liu, Yunjiang, Liu, Ke, Zhang, Jianguo, Mao, Dahua, Yu, Zhigang, Liu, Yinhua, Fu, Peifen, Wang, Jiandong, Jiang, Hongchuan, Zhao, Zuowei, Tian, Xingsong, Cao, Zhongwei, Wu, Kejin, Song, Ailin, Jin, Feng, He, Jianjun, Fan, Zhimin, Zhang, Huimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986903/ https://www.ncbi.nlm.nih.gov/pubmed/36891484 http://dx.doi.org/10.1177/17588359231156146 |
Ejemplares similares
-
The outcome of neoadjuvant chemotherapy and the current trend of surgical treatment in young women with breast cancer: A multicenter real-world study (CSBrS-012)
por: Li, Yijun, et al.
Publicado: (2023) -
Clinical practice guidelines for the diagnosis and treatment of inflammatory breast cancer: Chinese Society of Breast Surgery (CSBrS) Practice Guidelines 2022
por: Ma, Li, et al.
Publicado: (2023) -
Clinical characteristics and clinicopathological correlations of bilateral breast cancer in China: A multicenter study from Chinese Society of Breast Surgery (CSBrS-006)
por: Li, Xuelu, et al.
Publicado: (2021) -
Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)
por: Cheng, Yuanjia, et al.
Publicado: (2022) -
Clinical practice guideline for breast fibroadenoma: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021
por: Peng, Yuan, et al.
Publicado: (2021)